Hemophilia Research Studies

Clinical research brings improved therapies to market and provides an opportunity for patients to contribute to advance care and treatment. Clinical research may also improve overall understanding of bleeding and clotting disorders, increase knowledge of genetics, and provide ongoing safety information of therapy. Clinical research studies may offer you and your insurance carrier substantial free treatment and laboratory testing.

The IHTC has a long standing history of leadership in clinical research. The IHTC performed the first in the world human infusion of the following products:

  1. Genetically engineered factor IX concentrate
  2. Long-acting genetically engineered immunoglobulin fused factor IX concentrate
  3. Genetically engineered von Willebrand factor concentrate
  4. Genetically engineered bio-similar factor IX concentrate

The IHTC is a leader in clinical research with over 50 currently active studies available to eligible patients. There are a variety of different clinical research categories including pharmaceutical, investigator initiated, quality of life analyses and studies with national funding including the Centers for Disease Control and Prevention (CDC) or National Institute of Health (NIH).

The IHTC independently evaluates the need for a specific study weighing how it may impact future patient care; above all the safety of the project is critically evaluated.

Without you, these clinical studies would not be possible. You are the most important contributor to clinical advances. We encourage you to consider available studies and take part in ones that interest you.